201 related articles for article (PubMed ID: 19293807)
1. Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study.
Berney DM; Gopalan A; Kudahetti S; Fisher G; Ambroisine L; Foster CS; Reuter V; Eastham J; Moller H; Kattan MW; Gerald W; Cooper C; Scardino P; Cuzick J
Br J Cancer; 2009 Mar; 100(6):888-93. PubMed ID: 19293807
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort.
Fisher G; Yang ZH; Kudahetti S; Møller H; Scardino P; Cuzick J; Berney DM;
Br J Cancer; 2013 Feb; 108(2):271-7. PubMed ID: 23329234
[TBL] [Abstract][Full Text] [Related]
3. Ki-67 is an independent predictor of prostate cancer death in routine needle biopsy samples: proving utility for routine assessments.
Kammerer-Jacquet SF; Ahmad A; Møller H; Sandu H; Scardino P; Soosay G; Beltran L; Cuzick J; Berney DM
Mod Pathol; 2019 Sep; 32(9):1303-1309. PubMed ID: 30976102
[TBL] [Abstract][Full Text] [Related]
4. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.
Vergis R; Corbishley CM; Norman AR; Bartlett J; Jhavar S; Borre M; Heeboll S; Horwich A; Huddart R; Khoo V; Eeles R; Cooper C; Sydes M; Dearnaley D; Parker C
Lancet Oncol; 2008 Apr; 9(4):342-51. PubMed ID: 18343725
[TBL] [Abstract][Full Text] [Related]
5. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
Khatami A; Hugosson J; Wang W; Damber JE
Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
[TBL] [Abstract][Full Text] [Related]
6. p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer.
Kudahetti S; Fisher G; Ambroisine L; Foster C; Reuter V; Eastham J; Møller H; Kattan MW; Cooper CS; Scardino P; Cuzick J; Berney DM
BJU Int; 2009 Jul; 104(1):20-4. PubMed ID: 19239456
[TBL] [Abstract][Full Text] [Related]
7. Expression of p120, Ki-67 and PCNA as proliferation biomarkers in imprint smears of prostate carcinoma and their prognostic value.
Bantis A; Giannopoulos A; Gonidi M; Liossi A; Aggelonidou E; Petrakakou E; Athanassiades P; Athanassiadou P
Cytopathology; 2004 Feb; 15(1):25-31. PubMed ID: 14748788
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of the markers p53 and Ki-67 for their predictive value in prostate cancer.
Uzoaru I; Rubenstein M; Mirochnik Y; Slobodskoy L; Shaw M; Guinan P
J Surg Oncol; 1998 Jan; 67(1):33-7. PubMed ID: 9457254
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the Mayo model.
Tollefson MK; Karnes RJ; Kwon ED; Lohse CM; Rangel LJ; Mynderse LA; Cheville JC; Sebo TJ
Mayo Clin Proc; 2014 Mar; 89(3):308-18. PubMed ID: 24486077
[TBL] [Abstract][Full Text] [Related]
10. PSCA, Cox-2, and Ki-67 are independent, predictive markers of biochemical recurrence in clinically localized prostate cancer: a retrospective study.
Kim SH; Park WS; Park BR; Joo J; Joung JY; Seo HK; Chung J; Lee KH
Asian J Androl; 2017; 19(4):458-462. PubMed ID: 27232854
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in prostate cancer.
Stattin P
Scand J Urol Nephrol Suppl; 1997; 185():1-46. PubMed ID: 9249905
[TBL] [Abstract][Full Text] [Related]
12. Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy.
Aaltomaa S; Kärjä V; Lipponen P; Isotalo T; Kankkunen JP; Talja M; Mokka R
Anticancer Res; 2006; 26(6C):4873-8. PubMed ID: 17214354
[TBL] [Abstract][Full Text] [Related]
13. Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors.
Nariculam J; Freeman A; Bott S; Munson P; Cable N; Brookman-Amissah N; Williamson M; Kirby RS; Masters J; Feneley M
Asian J Androl; 2009 Jan; 11(1):109-18. PubMed ID: 19050681
[TBL] [Abstract][Full Text] [Related]
14. Histopathological variables and biomarkers enhancer of zeste homologue 2, Ki-67 and minichromosome maintenance protein 7 as prognosticators in primarily endocrine-treated prostate cancer.
Tolonen TT; Tammela TL; Kujala PM; Tuominen VJ; Isola JJ; Visakorpi T
BJU Int; 2011 Nov; 108(9):1430-8. PubMed ID: 21592298
[TBL] [Abstract][Full Text] [Related]
15. Automated Ki-67 labeling index assessment in prostate cancer using artificial intelligence and multiplex fluorescence immunohistochemistry.
Blessin NC; Yang C; Mandelkow T; Raedler JB; Li W; Bady E; Simon R; Vettorazzi E; Lennartz M; Bernreuther C; Fraune C; Jacobsen F; Krech T; Marx A; Lebok P; Minner S; Burandt E; Clauditz TS; Wilczak W; Sauter G; Heinzer H; Haese A; Schlomm T; Graefen M; Steurer S
J Pathol; 2023 May; 260(1):5-16. PubMed ID: 36656126
[TBL] [Abstract][Full Text] [Related]
16. Characterisation of biomolecular profiles in primary high-grade prostate cancer treated by radical prostatectomy.
Augustin H; Hammerer PG; Graefen M; Palisaar J; Daghofer F; Huland H; Erbersdobler A
J Cancer Res Clin Oncol; 2003 Nov; 129(11):662-8. PubMed ID: 14513368
[TBL] [Abstract][Full Text] [Related]
17. Prognostic relevance of proliferation markers (Ki-67, PHH3) within the cross-relation of ERG translocation and androgen receptor expression in prostate cancer.
Goltz D; Montani M; Braun M; Perner S; Wernert N; Jung K; Dietel M; Stephan C; Kristiansen G
Pathology; 2015 Dec; 47(7):629-36. PubMed ID: 26517642
[TBL] [Abstract][Full Text] [Related]
18. Effect of pathologic revision and Ki67 and ERG immunohistochemistry on predicting radical prostatectomy outcome in men initially on active surveillance.
Bokhorst LP; Roobol MJ; Bangma CH; van Leenders GJ
Prostate; 2017 Jul; 77(10):1137-1143. PubMed ID: 28543353
[TBL] [Abstract][Full Text] [Related]
19. Tissue microarray sampling strategy for prostate cancer biomarker analysis.
Rubin MA; Dunn R; Strawderman M; Pienta KJ
Am J Surg Pathol; 2002 Mar; 26(3):312-9. PubMed ID: 11859202
[TBL] [Abstract][Full Text] [Related]
20. Prognostic markers in clinically localised prostate cancer.
Bai XZ; Masters JR; O'Donoghue N; Kirby R; Pan LX; Young M; Stafford M; Parkinson MC
Int J Oncol; 1999 Apr; 14(4):785-91. PubMed ID: 10087330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]